Press Room

10 August 2016

Beyond anti-CD19 CARTs: the future of CAR T-cells depends on the convergence of technologies

STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a…

Read more

29 May 2016

Increasing impact of biosimilars on the market of originator therapeutic antibodies

STUTTGART, Germany I May 29, 2016 I 2015 was the last year without significant impact of biosimilars on the world of branded originator therapeutic antibodies in regulated markets. The targets of the first wave of biosimilar antibodies are the three…

Read more

13 May 2016

Improved next generation of T-cell redirecting bispecific antibodies enters clinical proof-of-concept phase

STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells…

Read more

13 March 2016

Biologics sales in 2015 exceeded the USD 150 bln threshold

STUTTGART, Germany I March 13, 2016 I 2015 was another year of record sales of recombinant therapeutic proteins and antibodies despite the beginning commercialization of biosimilar antibodies and proteins. Global sales of originator antibodies and proteins reached USD 154 bln,…

Read more

4 February 2016

RORgamma, a hot target for treatment of Th17 cell-mediated immune diseases, but also for immune therapy of cancer

STUTTGART, Germany I February 4, 2016 I Targeting the proinflammatory cytokine interleukin-17 (IL-17) produced by T helper cells has become a clinically validated strategy of successfully treating psoriasis, psoriatic arthritis and ankylosing spondylitis. The first approved and marketed antibody secukinumab…

Read more

2 December 2015

Antibody-drug conjugate technology on the path to productivity providing plenty of opportunities

STUTTGART, Germany I December 2, 2015 I Only a few years ago, before the times of immuno-oncology and chimeric antigen receptor (CAR) T-Cell Therapeutics, antibody-drug conjugates (ADC) were the most exciting investment opportunity in oncology which nobody wanted to miss.…

Read more

18 March 2015

Innovation with therapeutic antibodies drives 2014 sales of recombinant biologics

STUTTGART, Germany I March 18, 2015 I This year’s systematic comparison of the US$ sales of recombinant therapeutic antibodies and proteins in the year 2014 based on standardized currency exchange rates as of March 17, 2015 suffered from the strong…

Read more

12 March 2015

Engineered T-Cell Receptor and T-Cells: independent, but also complementary tools for immuno-oncology with great prospects

STUTTGART, Germany I March 12, 2015 I The T-Cell Receptor (TCR) has emerged as a means to target peptide antigens derived from intracellular proteins in a major histocompatibility complex (MHC) dependent manner. These peptide antigens are presented on the surface…

Read more

29 December 2014

Recombinant coagulation factors: market, products, R&D pipeline and new competition from alternative procoagulants and gene & cell therapy

STUTTGART, Germany I December 29, 2014 I Since approval of the first recombinant coagulation factors for treatment and prophylaxis of hemophilia A and B about two decades ago, the market of recombinant coagulation factors has constantly grown to a size…

Read more

16 July 2014

Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares (2)

STUTTGART, Germany I July 16, 2014 I A new business report entitled „Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders“ has been released by La Merie Publishing. The worldwide market for botulinum neurotoxins has grown with…

Read more

9 May 2014

Recombinant therapeutic antibodies consolidate as growth driver of biologics sales in 2013

STUTTGART, Germany I May 9, 2014 I La Merie Publishing announced today the release of its annual review of the sales of recombinant therapeutic antibodies and proteins. The compilation entitled „2013 Sales of Recombinant Therapeutic Antibodies & Proteins“ shows that…

Read more

23 January 2014

The exponential growth of the field of antibody-drug conjugates provides plenty of business opportunities

STUTTGART, Germany I January 23, 2014 I The area of antibody-drug conjugates (ADC) is a very fertile area for business ranging from partnerships between pharma and biotech or biotech and biotech up to contract services for conducting research and manufacturing…

Read more